Udayavni Special

RDIF, Hetero ink pact to produce 100 Mn doses of Sputnik V vaccine in India


PTI, Nov 27, 2020, 1:18 PM IST

Hyderabad: The Russian Direct Investment Fund, Russia’s sovereign wealth fund, and city-based pharma group Hetero have agreed to produce over 100 million doses per year of the world’s first registered COVID-19 vaccine Sputnik V, Hetero said on Friday.

The parties intend to start the production of Sputnik V in the beginning of 2021, through Hetero’s biologics arm Hetero Biopharma,” it said in a press release.

The Gamaleya Center in Russia and RDIF announced on November 24 positive results obtained during the second interim data analysis of the largest double-blind, randomised, placebo-controlled Phase III clinical trials in Russia’s history involving 40,000 volunteers.

Currently Phase III clinical trials are approved and are ongoing in Belarus, the UAE, Venezuela and other countries, as well as Phase II-III in India and requests for more than 1.2 billion doses of Sputnik V vaccine came from more than 50 countries.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said “We are delighted to announce the agreement between RDIF and Hetero that will pave the way to production of the safe and highly effective Sputnik V vaccine on Indian soil.

The vaccines interim clinical trial results show 95 per cent efficacy on the 42nd day after the first dose.

B Murali Krishna Reddy, Director International Marketing, Hetero Labs Limited, said “We are pleased to collaborate with RDIF as a manufacturing partner for the most anticipated Sputnik V vaccine for the treatment of Covid-19. While we look forward to the clinical trial results in India, we believe that manufacturing the product locally is crucial to enable swift access to patients.”

Reddy further said the collaboration is another step towards Hetero’s commitment in the battle against Covid-19 and realizing the objective of the ‘Make-in-India’ campaign as envisioned by Prime Minister Narendra Modi.

Earlier in September 2020,Dr. Reddy’s and Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India.

As part of the partnership,RDIF shall supply 100 million doses of the vaccine toDr.Reddys upon regulatory approval in India.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

On Republic Day farmers’ tractor, bike parade in B’luru: Kuruburu Shantakumar

Gadkari hopes reduction in road accidents, deaths in India by 50 pc before 2025

Making all efforts to extradite fugitive businessman Vijay Mallya: Centre to SC

Indian woman dies in UAE after husband accidentally rams car into her

Beltangady: SPDI leader challenges BJP vow in Dharmasthala

Protests erupt over Uddhav’s statement on border issue

NCP demands JPC on purported chats between Goswami, Dasgupta


Related Articles More

TKM ties up with government for skilling youths

Rafale to feature in Republic Day parade for first time

Gadkari hopes reduction in road accidents, deaths in India by 50 pc before 2025

Making all efforts to extradite fugitive businessman Vijay Mallya: Centre to SC

Rajini Mandram says its members are free to join any political party

MUST WATCH

I have not asked for a ministerial position: Halady Srinivasa Shetty

Staff nurse Shobha, first to be vaccinated against Covid at Dr. TMA Pai hospital

Ravi Katapadi, the hope of the poorest children, won 12.5 lakhs at KBC | Udayavani

Signal surges ahead of Whatsapp amid privacy concerns

What do vaccine experts say about confusion over the covid vaccine?

Latest Additions

Gangavati: Father, son on scooter killed on spot after collision with bus

On Republic Day farmers’ tractor, bike parade in B’luru: Kuruburu Shantakumar

TKM ties up with government for skilling youths

Rafale to feature in Republic Day parade for first time

Gadkari hopes reduction in road accidents, deaths in India by 50 pc before 2025

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.